Teva Pharmaceutical Industries (TEVA) Research & Development (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Research & Development came in at $970.0 million in Q2 2026, up 48.32% YoY from $654.0 million in Q2 2025, and up 39.37% on a QoQ basis from $696.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Research & Development (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Research & Development data on file, last reported at $970.0 million in Q2 2026.
- Quarterly Research & Development rose 48.32% year-over-year to $970.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.1 billion (up 20.49% YoY) and the FY2025 annual result came in at $2.7 billion, up 5.71% from the prior year.
- Research & Development improved to $970.0 million in Q2 2026, from $696.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $970.0 million in Q2 2026 to a low of $539.0 million in Q3 2022.
- A 5-year average of $638.4 million and a median of $616.0 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development decreased 13.0% — and 2026, when it surged 48.32%.
- Tracing TEVA's Research & Development over 5 years: stood at $549.0 million in 2022, then rose by 11.11% to $610.0 million in 2023, then grew by 6.56% to $650.0 million in 2024, then increased by 15.85% to $753.0 million in 2025, then grew by 28.82% to $970.0 million in 2026.
- The last three Research & Development figures came in at $970.0 million (Q2 2026), $696.0 million (Q1 2026), and $753.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.64 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.74 Bn | 22.95 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.26 Bn | 19.60 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.85 Bn | 17.96 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 12.15 Bn | 11.62 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.28 Bn | 7.62 Bn | 397.90 Mn | 154.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 970.00 Mn |
| Mar 31, 2026 | 696.00 Mn |
| Dec 31, 2025 | 753.00 Mn |
| Sep 30, 2025 | 656.00 Mn |
| Jun 30, 2025 | 654.00 Mn |
| Mar 31, 2025 | 622.00 Mn |
| Dec 31, 2024 | 650.00 Mn |
| Sep 30, 2024 | 626.00 Mn |
| Jun 30, 2024 | 656.00 Mn |
| Mar 31, 2024 | 608.00 Mn |
| Dec 31, 2023 | 610.00 Mn |
| Sep 30, 2023 | 576.00 Mn |
| Jun 30, 2023 | 603.00 Mn |
| Mar 31, 2023 | 546.00 Mn |
| Dec 31, 2022 | 549.00 Mn |
| Sep 30, 2022 | 539.00 Mn |
| Jun 30, 2022 | 594.00 Mn |
| Mar 31, 2022 | 584.00 Mn |
| Dec 31, 2021 | 631.00 Mn |
| Sep 30, 2021 | 597.00 Mn |